Evidence map›Paper›PMID 33940788›Full record

ArticleCancer research and treatment2022

Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).

Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Hyo Jung Kim, Keun-Wook Lee, Min Kyoung Kim and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. [Predictive value ofZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 1 country.

Yun-Gyoo LeeDepartment of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Eun Joo KangDepartment of Internal Medicine, Korea University Guro Hospital, Seoul, Korea.
Bhumsuk KeamDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Jin-Hyuk ChoiDepartment of Hematology-Oncology, Ajou University Hospital, Suwon, Korea.
Jin-Soo KimDepartment of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea.
Keon Uk ParkDepartment of Hemato-Oncology, Keimyung University Dongsan Medical Center, Daegu, Korea.
Kyoung Eun LeeDepartment of Hematology and Oncology, Ewha Womans University Hospital, Seoul, Korea.
Hyo Jung KimDepartment of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Keun-Wook LeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Min Kyoung KimDepartment of Hematology-Oncology, Yeungnam University Medical Center, Daegu, Korea.
Hee Kyung AhnDepartment of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Seong Hoon ShinDepartment of Internal Medicine, Kosin University Gospel Hospital, Busan, Korea.
Hye Ryun KimDepartment of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Sung-Bae KimDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hwan Jung YunDepartment of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
Seoul National University Bundang Hospital · KRYonsei University · KRAjou University Hospital · KRAsan Medical Center · KRChungnam National University Hospital · KRGachon University Gil Medical Center · KRKangbuk Samsung Hospital · KRKeimyung University · KRKorea University Medical Center · KRKosin University Gospel Hospital · KRSeoul National University Hospital · KRSNUH SMG-SNU Boramae Medical Center · KRYeungnam University Medical Center · KR

Funding

KCSG data centerKorean Cancer Study GroupMinistry of Health and Welfare HA16C0015
6 · The paper itself

Abstract

purposeCertain patient subgroups who do not respond to induction chemotherapy (IC) show inherent chemoresistance in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This study aimed to assess the prognostic value of IC, and role of IC in guiding the selection of a definitive locoregional therapy. MATERIALS AND

methodsOut of the 445 patients in multi-institutional LA-HNSCC cohort, 158 (36%) receiving IC were enrolled. The study outcome was to assess overall survival (OS) through IC responsiveness and its role to select subsequent treatments.

resultsAmong 135 patients who completed subsequent treatment following IC, 74% responded to IC (complete response in 17% and partial response in 58%). IC-non-responders showed 4.5 times higher risk of mortality than IC-responders (hazard ratio, 4.52; 95% confidence interval, 2.32 to 8.81; p < 0.001). Among IC-responders, 84% subsequently received definitive concurrent chemoradiotherapy (CCRT) and OS was not differed by surgery or CCRT (p=0.960). Regarding IC-non-responders, 54% received CCRT and 46% underwent surgery, and OS was poor in CCRT (24-month survival rate of 38%) or surgery (24-month survival rate of 63%).

conclusionResponse to IC is a favorable prognostic factor. For IC-responders, either surgery or CCRT achieved similar survival probabilities. For IC-non-responder, multidisciplinary approach was warranted reflecting patients' preference, morbidity, and prognosis.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinDocetaxelDrug Resistance, NeoplasmFemaleFluorouracilFollow-Up StudiesHead and Neck NeoplasmsHumansInduction ChemotherapyMaleMiddle AgedRetrospective StudiesSquamous Cell Carcinoma of Head and NeckCisplatinDocetaxelFluorouracilInduction chemotherapyLocally advanced head and neck squamous cell carcinomaSubsequent treatment

Identifiers

PMID33940788
PMCPMC8756113
OpenAlexW3157760365

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.